Wooridul Huebrain Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 02:39 am EST
Share
Wooridul Huebrain Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 766 million compared to KRW 49.84 million a year ago. Net loss was KRW 10,956.1 million compared to KRW 4,173.99 million a year ago. Basic loss per share from continuing operations was KRW 127 compared to KRW 57 a year ago. Basic loss per share was KRW 127 compared to KRW 57 a year ago.
For the nine months, sales was KRW 2,311.83 million compared to KRW 105.13 million a year ago. Net loss was KRW 30,291.76 million compared to net income of KRW 5,451.69 million a year ago. Basic loss per share from continuing operations was KRW 362 compared to basic earnings per share from continuing operations of KRW 126 a year ago. Basic loss per share was KRW 362 compared to basic earnings per share of KRW 91 a year ago.
SMeDi Co Ltd, formerly The MediPharm Co Ltd, is a Korea-based company primarily engaged in the pharmaceutical distribution business. The Company operates through five segments. The Pharmaceuticals Business segment is engaged in the distribution of pharmaceuticals including recapsules and tablets. The Medical Business segment is engaged in the distribution of medical devices and medical supplies. The Wireless Device segment is engaged in the manufacture of wearable wireless devices. The Video Content segment is engaged in the production of video products. The Investment segment is engaged in the management consulting and investment businesses.
SMEDI CO., LTD. 
